Screening the medicines for malaria venture "malaria box" against the plasmodium falciparum aminopeptidases, M1, M17 and M18

Alessandro Paiardini, Rebecca S Bamert, Komagal Kannan Sivaraman, Nyssa Drinkwater, Shailesh N Mistry, Peter J Scammells, Sheena McGowan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessarily the molecular targets. In this study, we assess the ability of the MMV 400 compounds to inhibit the activity of three metalloaminopeptidases from Plasmodium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopeptidases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopeptidases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordination or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA-M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity reported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors utilising non-classical zinc binding groups.
Original languageEnglish
Article numbere0115859
Number of pages14
JournalPLoS ONE
Volume10
Issue number2
DOIs
Publication statusPublished - 2015

Cite this

Paiardini, Alessandro ; Bamert, Rebecca S ; Kannan Sivaraman, Komagal ; Drinkwater, Nyssa ; Mistry, Shailesh N ; Scammells, Peter J ; McGowan, Sheena. / Screening the medicines for malaria venture "malaria box" against the plasmodium falciparum aminopeptidases, M1, M17 and M18. In: PLoS ONE. 2015 ; Vol. 10, No. 2.
@article{e78d03b1436f4f3a9d7e94d76b6c1722,
title = "Screening the medicines for malaria venture {"}malaria box{"} against the plasmodium falciparum aminopeptidases, M1, M17 and M18",
abstract = "Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessarily the molecular targets. In this study, we assess the ability of the MMV 400 compounds to inhibit the activity of three metalloaminopeptidases from Plasmodium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopeptidases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopeptidases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordination or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA-M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity reported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors utilising non-classical zinc binding groups.",
author = "Alessandro Paiardini and Bamert, {Rebecca S} and {Kannan Sivaraman}, Komagal and Nyssa Drinkwater and Mistry, {Shailesh N} and Scammells, {Peter J} and Sheena McGowan",
year = "2015",
doi = "10.1371/journal.pone.0115859",
language = "English",
volume = "10",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

Screening the medicines for malaria venture "malaria box" against the plasmodium falciparum aminopeptidases, M1, M17 and M18. / Paiardini, Alessandro; Bamert, Rebecca S; Kannan Sivaraman, Komagal; Drinkwater, Nyssa; Mistry, Shailesh N; Scammells, Peter J; McGowan, Sheena.

In: PLoS ONE, Vol. 10, No. 2, e0115859, 2015.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Screening the medicines for malaria venture "malaria box" against the plasmodium falciparum aminopeptidases, M1, M17 and M18

AU - Paiardini, Alessandro

AU - Bamert, Rebecca S

AU - Kannan Sivaraman, Komagal

AU - Drinkwater, Nyssa

AU - Mistry, Shailesh N

AU - Scammells, Peter J

AU - McGowan, Sheena

PY - 2015

Y1 - 2015

N2 - Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessarily the molecular targets. In this study, we assess the ability of the MMV 400 compounds to inhibit the activity of three metalloaminopeptidases from Plasmodium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopeptidases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopeptidases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordination or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA-M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity reported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors utilising non-classical zinc binding groups.

AB - Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessarily the molecular targets. In this study, we assess the ability of the MMV 400 compounds to inhibit the activity of three metalloaminopeptidases from Plasmodium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopeptidases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopeptidases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordination or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA-M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity reported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors utilising non-classical zinc binding groups.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336144/pdf/pone.0115859.pdf

U2 - 10.1371/journal.pone.0115859

DO - 10.1371/journal.pone.0115859

M3 - Article

VL - 10

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 2

M1 - e0115859

ER -